Blackstone Inc Alnylam Pharmaceuticals, Inc. Transaction History

Blackstone Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $62.3 Million - $87.6 Million	-517,391 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $15.5 Million - $21.3 Million	-120,436 Reduced 18.88%	517,391 $87.7 Million
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $21.9 Million - $26.2 Million	-178,245 Reduced 21.84%	637,827 $82.9 Million
Q3 2020 Nov 16, 2020	SELL	$121.19 - $165.49 $13.2 Million - $18 Million	-108,609 Reduced 11.75%	816,072 $119 Million
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $96.4 Million - $145 Million	924,681 New	924,681 $137 Million

642

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Blackstone Inc, based on Form 13F filings with the SEC.

Stay updated on Blackstone Inc with notifications on news.